



Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1

of

3

Complete if Known

Application Number	10/524,233
Filing Date	August 6, 2003
First Named Inventor	Alexander B. ROSSI
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	375462-003US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A/B M/D	A1	US-6,897,031			
	A2	US-20030027763			
	A3	US-20030077824			
	A4	US-20030190684			
	A5	US-20040029902			
	A6				
	A7				
	A8				
	A9				
	A10				
	A11				
	A12				
	A13				
	A14				
	A15				
	A16				
	A17				
	A18				
	A19				
	A20				
	A21				
	A22				
	A23				
	A24				
	A25				
	A26				
	A27				
	A28				
	A29				
	A30				
	A31				
	A32				
	A33				
	A34				
	A35				
	A36				

Examiner
Signature

Date
Considered

8/22/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/524,233	
			Filing Date	August 6, 2003	
			First Named Inventor	Alexander B. ROSSI	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	375462-003US

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
M/	B1	WO2004015389	12/19/2004	Rigel Pharmaceuticals, Inc.		
	B2	WO03/074652	09/12/2003	Regents of Univ. of California		
	B3	WO03/020896	03/13/2003	Rigel Pharmaceuticals, Inc.		
	B4	WO02/101071 ✓	12/19/2002	Rigel Pharmaceuticals, Inc.		
	B5	WO98/55152 ✓	12/10/1998	Baylor College of Medicine		
M/	B6	PCT Int'l. Search Report	04/19/2004			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
M/	C1	Agis et al., 1996, "Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes," <i>Immunology</i> 87:535-43.	
	C2	Demo et al., 1999, "Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay," <i>Cytometry</i> 36(4):340-8. ✓	
	C3	Dombrowicz et al., 1998, Allergy-Associated FcRβ Is a Molecular Amplifier of IgE- and IgE-Mediated In Vivo Responses," <i>Immunity</i> 8(4):517-529.	
	C4	Galli and Lantz, 1999, "Allergy" in <i>Fundamental Immunology</i> , 5 th Ed., Paul, W.E. ed., Lippincott-Raven Publishers, New York, pg. 1130-1142.	
	C5	Ghannadan et al., 1998, "Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies," <i>J. Invest Dermatol</i> 111(4):689-95.	
	C6	Gilmore et al., 2000, Ex vivo expansion of human umbilical cord blood and peripheral blood CD34+ hematopoietic stem cells," <i>Exp. Hematol.</i> 28(11):1297-1305.	
	C7	Gross et al., 2002, "SWAP-70-deficient mast cells are impaired in development and IgE-mediated degranulation," <i>Eur J Immunol.</i> 32(4):1121-8.	
	C8	Igarashi et al., 1996, "Characterization of histamine release from cultured human mast cells," <i>Clin Exp Allergy</i> 26(5):597-602. ✓	
	C9	Katz et al., 1992, "Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells," <i>J. Immunol.</i> 148(3):868-871.	
	C10	Matsuda et al., 1997, "Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NV/Nga mice" <i>Int. Immunol.</i> 9(3):461-466.	
	C11	Okayama et al., 2000, Expression of a functional high-affinity IgG receptor, FcRγ1, on human mast cells: Up-regulation by IFN-γ," <i>J. Immunol.</i> 164(8):4332-4339.	
	C12	Saito et al., 1995, "Characterization of cord-blood derived human mast cells cultured in the presence of steel factor and interleukin-6," <i>Int. Arch. Allergy Immunol.</i> 107:63-65.	
	C13	Saito et al., 1996, "Selective growth of human mast cells induced by steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells," <i>J. Immunol.</i> 157(1):343-350.	
	C14	Suzuki et al., 1997, "Early and late events in FcεR1 signal transduction in human cultured mast cells," <i>J Immunol.</i> 159(12):5881-8. ✓	
M/	C15	Toru et al., 1996, "Induction of high-affinity IgE receptor (FcεR1) on human mast cells by IL-4," <i>Int. Immunol.</i> 8(9):1367-1373.	

Examiner Signature	Date Considered
	8/22/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/524,233	
			Filing Date	August 6, 2003	
			First Named Inventor	Alexander B. ROSSI	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	375462-003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Citation No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
MB	C16	Valent et al., 1992, "Cell surface structures on human basophils and mast cells: biochemical and functional characterization," <i>Adv. Immunol.</i> 52:335-339.	
MA	C17	Yamaguchi et al., 1999, "IgE enhances Fcε Receptor I expression and IgE dependent release of histamine and lipid mediators from human umbilical cord blood derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fcε receptor I expression and mediator release," <i>J Immunol.</i> 162(9):5455-65.	!!!
	C18		
	C19		
	C20		
	C21		
	C22		
	C23		
	C24		
	C25		
	C26		
	C27		
	C28		
	C29		
	C30		
	C31		
	C32		
	C33		
	C34		
	C35		
	C36		

Examiner Signature		Date Considered	8/22/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2